Literature DB >> 465287

Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance.

S Vozeh, P Spring, M Wenk, F Follath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 465287      PMCID： PMC1429668          DOI： 10.1111/j.1365-2125.1979.tb04656.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys.

Authors:  B A Halpren; S G Axline; N S Coplon; D M Brown
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

2.  Enzymatic assay for gentamicin and related aminoglycoside antibiotics.

Authors:  R K Holmes; J P Sanford
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

3.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

4.  [Elimination kinetics of gentamicin in kidney insufficiency].

Authors:  P Spring; M Bürgi
Journal:  Schweiz Rundsch Med Prax       Date:  1973-04-10

5.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

6.  Some considerations as to the determination and significance of biologic half-life.

Authors:  M Gibaldi; H Weintraub
Journal:  J Pharm Sci       Date:  1971-04       Impact factor: 3.534

7.  Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration.

Authors:  M C McHenry; T L Gavan; R W Gifford; N A Geurkink; R A Van Ommen; M A Town; J G Wagner
Journal:  Ann Intern Med       Date:  1971-02       Impact factor: 25.391

8.  Gentamicin disposition and tissue accumulation on multiple dosing.

Authors:  J J Schentag; W J Jusko; J W Vance; T J Cumbo; E Abrutyn; M DeLattre; L M Gerbracht
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

Review 9.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

10.  Accumulation pharmacokinetics of tobramycin.

Authors:  J J Schentag; G Lasezkay; T J Cumbo; M E Plaut; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191
View more
  5 in total

1.  Population pharmacokinetics of tobramycin.

Authors:  L Aarons; S Vozeh; M Wenk; P Weiss; F Follath
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

2.  Pharmacokinetic and pathological evaluation of gentamicin in cats given a small intravenous dose repeatedly for five days.

Authors:  A D Jernigan; R C Hatch; J Brown; W A Crowell
Journal:  Can J Vet Res       Date:  1988-04       Impact factor: 1.310

3.  Increase of amikacin half-life during therapy in patients with renal insufficiency.

Authors:  J Blaser; S Rüttimann; H Bhend; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

4.  Population pharmacokinetics of netilmicin in short-term prophylactic treatment.

Authors:  Nerea Jauregizar; Jeff A Wald; Ander Astobieta; Jose M Rodriguez Sasiain; John C Lukas; Rosario Calvo
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

Review 5.  Serum level monitoring of antibacterial drugs. A review.

Authors:  M Wenk; S Vozeh; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.